After several months of crisis, we can discern some of the key lessons learned from COVID-19 for the future of pharmaceutical policy in Europe.
News & Trends
Procurar
Recentes
- Update to EU GMP Guidelines – Revised Annex 19 on Reference and Retention Samples
- FARMACOVIGILÂNCIA nível avançado : Formação completa con casos práticos
- FDA DRAFT GUIDANCE :Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products
- European Biotech Act: Positioning EU as Biotech Powerhouse
- CIOMS Glossary of ICH Terms and Definitions. Version 10
- Guidance on standardisation for medical devices Appendix: Transition to the ‘EU REP’ symbol in EN ISO 15223-1
- MDCG Position Paper: Management of SS(C)P in EUDAMED after mandatory use
- Commission Implementing Decision amending Implementing Decision (EU) 2021/1195 as regards the harmonised standard for symbols to be used with information to be supplied by the manufacturer